Thalidomide in primary peritoneal mesothelioma

Journal of Surgical Oncology

Volumn 93, Issue 5, 2006, Pages 434-

  Biswas, Ghanashyam ^a   Narayanan, Prasad ^a   Bhagwat, Roshni ^a   Khadwal, Alka ^a   Bakshi, Ashish V ^a   Parikh, Purvish M ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ASBESTOS; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN; DOXORUBICIN; PACLITAXEL; THALIDOMIDE; VIMENTIN;

ABDOMINAL SURGERY; ADULT; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FOLLOW UP; HUMAN; LETTER; MALE; NEUROPATHY; OCCUPATIONAL EXPOSURE; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; MESOTHELIOMA; MIDDLE AGED; NOTE; PERITONEUM TUMOR;

ANGIOGENESIS INHIBITORS; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; THALIDOMIDE;

EID: 33646192332     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20458     Document Type: Letter

References (5)

1. Bani-Hani KE, Gharaibeh KA: Malignant peritoneal mesothelioma. J Surg Oncol 2005;91:17-25.
2. Mohamed F, Sugarbaker PH: Peritoneal mesothelioma. Curr Treat Options Oncol 2002;3:375-386.
3. Soulie P, Ruffie P, Trandafir L, et al.: Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996;14:878-885.
4. Hoff CM, Shockley TR: The potential of gene therapy in the peritoneal cavity. Perit Dial Int 1999;19:S202-S207.
5. Hada M, Kazuhiro M: A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP. Gan To Kagaku Ryoho 2004;31:2191-2194.